Staging of Liver Disease. Which Option is Right for My Patient?

Infectious Disease Clinics of North America

Volumn 26, Issue 4, 2012, Pages 849-861

  Bhogal, Harjit ^a   Sterling, Richard K ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Hepatitis C; Liver fibrosis; Noninvasive staging

Indexed keywords

ANTIVIRUS AGENT; BIOLOGICAL MARKER; BOCEPREVIR; PEGINTERFERON; RIBAVIRIN; TELAPREVIR;

ALGORITHM; ASPARTATE AMINOTRANSFERASE PLATELET RATIO INDEX; BLOOD EXAMINATION; BREATH ANALYSIS; CLINICAL ASSESSMENT TOOL; DISEASE CLASSIFICATION; ECHOGRAPHY; FIB 4; FIBROTEST; FORNS INDEX; HEPATITIS C; HUMAN; INTERMETHOD COMPARISON; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; REVIEW; RISK BENEFIT ANALYSIS; STAGING; TREATMENT DURATION; BIOPSY; DIAGNOSTIC IMAGING; METABOLISM; PATHOLOGY; SEVERITY OF ILLNESS INDEX; VIROLOGY;

ALGORITHMS; BIOLOGICAL MARKERS; BIOPSY; DIAGNOSTIC IMAGING; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; SEVERITY OF ILLNESS INDEX;

EID: 84867662796     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2012.08.002     Document Type: Review

References (60)

1. Ghany M.G., Strader D.B., Thomas D.L., et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374.
2. Cadranel J.F., Rufat P., Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000, 32:477-481.
3. Piccinino F., Sagnelli E., Pasquale G., et al. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol 1986, 2:165-173.
4. Seeff L.B., Everson G.T., Morgan T.R., et al. Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol 2010, 8:877-883.
5. Sterling R.K., Lyons C.D., Stravitz R.T., et al. Percutaneous liver biopsy in adult haemophiliacs with hepatitis C virus: safety of outpatient procedure and impact of human immunodeficiency virus coinfection on the spectrum of liver disease. Haemophilia 2007, 13:164-171.
6. Sterling R.K., Sanyal A.J., Luketic V.A., et al. Chronic hepatitis C infection in patients with end stage renal disease: characterization of liver histology and viral load in patients awaiting renal transplantation. Am J Gastroenterol 1999, 94:3576-3582.
7. Regev A., Berho M., Jeffers L.J., et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002, 97:2614-2618.
8. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994, 20:15-20.
9. Schiano T.D., Azeem S., Bodian C.A., et al. Importance of specimen size in accurate needle liver biopsy evaluation of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2005, 3:930-935.
10. Bedossa P., Dargere D., Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003, 38:1449-1457.
11. Wai C.T., Greenson J.K., Fontana R.J., et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003, 38:518-526.
12. Snyder N., Gajula L., Xiao S.Y., et al. APRI: an easy and validated predictor of hepatic fibrosis in chronic hepatitis C. J Clin Gastroenterol 2006, 40:535-542.
13. Al-Mohri H., Cooper C., Murphy T., et al. Validation of a simple model for predicting liver fibrosis in HIV/hepatitis C virus-coinfected patients. HIV Med 2005, 6:375-378.
14. Shaheen A.A., Myers R.P. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology 2007, 46:912-921.
15. Forns X., Ampurdanes S., Llovet J.M., et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002, 36:986-992.
16. Sterling R.K., Lissen E., Clumeck N., et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006, 43:1317-1325.
17. Vallet-Pichard A., Mallet V., Nalpas B., et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 2007, 46:32-36.
18. Imbert-Bismut F., Ratziu V., Pieroni L., et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001, 357:1069-1075.
19. Usluer G., Erben N., Aykin N., et al. Comparison of non-invasive fibrosis markers and classical liver biopsy in chronic hepatitis C. Eur J Clin Microbiol Infect Dis 2012, 31(8):1873-1878.
20. Zarski J.P., Sturm N., Guechot J., et al. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. J Hepatol 2012, 56:55-62.
21. Boursier J., Bacq Y., Halfon P., et al. Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C. Eur J Gastroenterol Hepatol 2009, 21:28-38.
22. Martinez S.M., Crespo G., Navasa M., et al. Noninvasive assessment of liver fibrosis. Hepatology 2011, 53:325-335.
23. Mehta S.H., Lau B., Afdhal N.H., et al. Exceeding the limits of liver histology markers. J Hepatol 2009, 50:36-41.
24. Rosenberg W.M., Voelker M., Thiel R., et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004, 127:1704-1713.
25. Fontana R.J., Goodman Z.D., Dienstag J.L., et al. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology 2008, 47:789-798.
26. Leroy V., Monier F., Bottari S., et al. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol 2004, 99:271-279.
27. Fontana R.J., Dienstag J.L., Bonkovsky H.L., et al. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut 2010, 59:1401-1409.
28. Kettaneh A., Marcellin P., Douvin C., et al. Features associated with success rate and performance of FibroScan measurements for the diagnosis of cirrhosis in HCV patients: a prospective study of 935 patients. J Hepatol 2007, 46:628-634.
29. Sandrin L., Fourquet B., Hasquenoph J.M., et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003, 29:1705-1713.
30. Rizzo L., Calvaruso V., Cacopardo B., et al. Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C. Am J Gastroenterol 2011, 106:2112-2120.
31. Bavu E., Gennisson J.L., Couade M., et al. Noninvasive in vivo liver fibrosis evaluation using supersonic shear imaging: a clinical study on 113 hepatitis C virus patients. Ultrasound Med Biol 2011, 37:1361-1373.
32. Mitchell D.G., Navarro V.J., Herrine S.K., et al. Compensated hepatitis C: unenhanced MR imaging correlated with pathologic grading and staging. Abdom Imaging 2008, 33:58-64.
33. Wang Y., Ganger D.R., Levitsky J., et al. Assessment of chronic hepatitis and fibrosis: comparison of MR elastography and diffusion-weighted imaging. AJR Am J Roentgenol 2011, 196:553-561.
34. Huwart L., Sempoux C., Vicaut E., et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology 2008, 135:32-40.
35. Braden B., Faust D., Sarrazin U., et al. 13C-methacetin breath test as liver function test in patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther 2005, 21:179-185.
36. Lalazar G., Pappo O., Hershcovici T., et al. A continuous 13C methacetin breath test for noninvasive assessment of intrahepatic inflammation and fibrosis in patients with chronic HCV infection and normal ALT. J Viral Hepat 2008, 15:716-728.
37. Giannini E., Fasoli A., Chiarbonello B., et al. 13C-aminopyrine breath test to evaluate severity of disease in patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther 2002, 16:717-725.
38. Everson G.T., Shiffman M.L., Hoefs J.C., et al. Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: results from the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial. Hepatology 2012, 55:1019-1029.
39. Sebastiani G., Halfon P., Castera L., et al. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology 2009, 49:1821-1827.
40. Sebastiani G., Halfon P., Castera L., et al. Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C. Aliment Pharmacol Ther 2012, 35:92-104.
41. Castera L., Sebastiani G., Le Bail B., et al. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol 2010, 52:191-198.
42. Bourliere M., Penaranda G., Renou C., et al. Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies. J Viral Hepat 2006, 13:659-670.
43. Leroy V., Hilleret M.N., Sturm N., et al. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol 2007, 46:775-782.
44. Ghany M.G., Nelson D.R., Strader D.B., et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011, 54:1433-1444.
45. Garcia-Tsao G., Sanyal A.J., Grace N.D., et al. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007, 46:922-938.
46. Smith J.O., Sterling R.K. Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C. Aliment Pharmacol Ther 2009, 30:557-576.
47. Benlloch S., Heredia L., Barquero C., et al. Prospective validation of a noninvasive index for predicting liver fibrosis in hepatitis C virus-infected liver transplant recipients. Liver Transpl 2009, 15:1798-1807.
48. Watt K., Uhanova J., Gong Y., et al. Serum immunoglobulins predict the extent of hepatic fibrosis in patients with chronic hepatitis C virus infection. J Viral Hepat 2004, 11:251-256.
49. Lorenzo-Zuniga V., Bartoli R., Masnou H., et al. Serum concentrations of insulin-like growth factor-I (igf-I) as a marker of liver fibrosis in patients with chronic hepatitis C. Dig Dis Sci 2007, 52:3245-3250.
50. Gangadharan B., Antrobus R., Dwek R.A., et al. Novel serum biomarker candidates for liver fibrosis in hepatitis C patients. Clin Chem 2007, 53:1792-1799.
51. Larrousse M., Laguno M., Segarra M., et al. Noninvasive diagnosis of hepatic fibrosis in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr 2007, 46:304-311.
52. Yilmaz S., Bayan K., Tuzun Y., et al. Replacement of histological findings: serum hyaluronic acid for fibrosis, high-sensitive C-reactive protein for necroinflammation in chronic viral hepatitis. Int J Clin Pract 2007, 61:438-443.
53. Murawaki Y., Koda M., Okamoto K., et al. Diagnostic value of serum type IV collagen test in comparison with platelet count for predicting the fibrotic stage in patients with chronic hepatitis C. J Gastroenterol Hepatol 2001, 16:777-781.
54. Bantel H., Lugering A., Poremba C., et al. Caspase activation correlates with the degree of inflammatory liver injury in chronic hepatitis C virus infection. Hepatology 2001, 34:758-767.
55. Zhang Q., Takahashi M., Noguchi Y., et al. Plasma amino acid profiles applied for diagnosis of advanced liver fibrosis in patients with chronic hepatitis C infection. Hepatol Res 2006, 34:170-177.
56. Zaman A., Rosen H.R., Ingram K., et al. Assessment of FIBROSpect II to detect hepatic fibrosis in chronic hepatitis C patients. Am J Med 2007, 120(280):e9-e14.
57. Koda M., Matunaga Y., Kawakami M., et al. FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology 2007, 45:297-306.
58. Kelleher T.B., Mehta S.H., Bhaskar R., et al. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol 2005, 43:78-84.
59. Berenguer J., Bellon J.M., Miralles P., et al. Identification of liver fibrosis in HIV/HCV-coinfected patients using a simple predictive model based on routine laboratory data. J Viral Hepat 2007, 14:859-869.
60. Parkes J., Guha I.N., Roderick P., et al. Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C. J Viral Hepat 2011, 18:23-31.